GSK announced Wednesday that revenue in the first quarter of fiscal 2024 was £7.36 billion, up 6% from the same quarter in 2023 on an AER basis and exceeding expectations. Total operating profit for the first quarter came at £1.5 billion. Total earnings per share increased 30% year-on-year to 25.7p
For 2024, GSK anticipates a turnover growth ranging between 5% and 7%, along with core EPS growth of 8% to 10%. Regarding dividends, the company declared a dividend of 15p for the first quarter of 2024 and 60p for the entire year.
"We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines […] We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024," CEO Emma Walmsley noted.